Abbott Laboratories (NYSE:ABT) shares jump after a broad-based quarterly beat across medical devices, diagnostics, and ...

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, ...

Furthermore, Abbott Laboratories (NYSE:ABT) reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, ...

Freenome (FRNM) and Abbott Laboratories (ABT) said Monday that the US Food and Drug Administration approved SimpleScreen CRC, a blood-based colorectal cancer screening test. The c ...

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual ...

The multiyear partnership will connect Abbott’s over-the-counter Lingo sensor and the Google Health app.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott’s valuation debate sharpens as legal pressure eases and medical devices, diagnostics, earnings quality, and future cash generation support its outlook.

Abbott Laboratories had higher revenue in the second quarter, boosted by more sales in its diagnostics business. The healthcare company on Thursday said its profit fell to $928 million, or 53 cents a ...

Aug 7 (Reuters) - Grail said on Friday the U.S. FDA plans to hold a meeting of outside experts to review its multi-cancer ...

The FDA has approved Freenome’s new blood-based colorectal cancer test, SimpleScreen CRC, which Abbott will exclusively market in the U.S. Abbott will pay Freenome $100 million as part of a 2025 deal ...